Landmark analysis at MRD final assessment for survival by MRD status. (A) Median PFS not reached in both groups; relapses among MRD-positive patients were 23/91; relapses among MRD-negative patients were 1/70 (P < .001). (B) Median OS not reached in both groups; deaths among MRD-positive patients were 11/91; there were no deaths among MRD-negative patients (P = .006).